Outlook Therapeutics, Inc. (OTLK): Nasdaq/NYSE listing notice — Outlook Therapeutics receives Nasdaq minimum bid price deficiency notice; 180-day cure period

Outlook Therapeutics, Inc.

Received Nasdaq letter on Feb 18, 2026, for closing bid price below $1.00 for 30 consecutive business days.
Has 180 calendar days, until August 17, 2026, to regain compliance.
To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days.
If not compliant by Aug 17, may be eligible for additional 180-day period if it meets other standards.
Company will monitor bid price and evaluate options including reverse stock split.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Outlook Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accord

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-017118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.